Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT 2: imatinib versus dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia
2007-006185-15Phase 3Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Feb 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Glivec arm with Sprycel arm (2 arms). Primary endpoint: 5-year event-free survival. Started Feb 2008; status: completed.
02
Drugs
imatinibdasatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2007-006185-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006185-15.